T

he Colombian government remains in the crosshairs of the pharmaceutical industry.

In comments filed with the US trade representative, the Pharmaceutical Research & Manufacturers of America argued that Colombia should be given added scrutiny for purportedly failing to sufficiently protect and enforce patent rights. The remarks from the trade group were submitted as the US Trade Rep prepares its priority watch list of countries that are singled out for practices deemed both favorable and unfavorable to American companies.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories